What is MND SMART?

MND SMART (Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial) is 'multi-arm' meaning more than one treatment will be tested at the same time. In the first instance the trial will have 3 arms; drug 1 (Memantine Hydrochloride - phase 2), drug 2 (Trazodone Hydrochloride - phase 3) and placebo (dummy drug). This allows the evaluation of drug 1 versus placebo and separately drug 2 versus placebo. Participants will be randomly allocated to either drug 1, drug 2 or placebo. Medicines being tested are already approved for use in other conditions. Currently recruiting in trial centres across the UK.

New drugs will be selected for investigation in MND-SMART based on continuous review of constantly updated scientific evidence as well as findings from state-of-the-art human stem cell based drug discovery platforms.

For more information, you can see our take part in research webpage.

What do the drugs do?

The trial is currently recruiting in the UK and Republic of Ireland at the following sites:

  • Edinburgh
  • Dundee
  • Glasgow
  • Aberdeen
  • Inverness
  • Southampton
  • Exeter
  • Salford
  • St George's London
  • West Suffolk
  • Ipswich, Norfolk
  • Birmingham
  • Newcastle
  • Cambridge

Find out more and register your interest to take part here.

Latest News

April 2022 - An independent review concluded that testing for both current drugs (Memantine and Trazodone) should be continued. Find out more here.

Jan 2022 - Over 260 participants have been recruited from 16 sites across the UK.


Want to find out more about MND SMART? Check out the resources below:


MND-SMART | Clinical trials for MND.

Last updated: 01/08/2022